Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
Top Cited Papers
Open Access
- 6 June 2013
- journal article
- Published by American Society of Hematology in Blood
- Vol. 121 (23), 4655-4662
- https://doi.org/10.1182/blood-2013-01-480228
Abstract
Key Points Azacytidine and sorafenib are effective in patients with relapsed and refractory FLT3-mutated AML.Keywords
This publication has 48 references indexed in Scilit:
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemiaNature, 2012
- CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursorsLeukemia, 2011
- p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemiaLeukemia, 2011
- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapseBlood, 2011
- FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivoBlood, 2011
- A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemiasLeukemia, 2010
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Blood, 2009
- Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsBlood, 2006
- Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitorsBlood, 2006
- Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathwaysBlood, 2006